【24h】

REMOVAL OF PHARMACEUTICAL CONTAMINANTS IN WATER

机译:去除水中的药物污染物

获取原文

摘要

Pharmaceutical contaminants in drinking water could potentially lead to increasing risks of heart attacks, organ damage, mental health and even cancer. Because their presence, frequency of occurrence, or source may not be known, the chemicals being discovered in water that previously had not been detected or are being detected at levels that may be significantly different than expected. Removal of emerging contaminants is considered recently to be one of the most important processes within advanced Waste Water Treatment Plants (WWTPs) system. EPA is working to improve its understanding of a number of emerging contaminants, particularly Pharmaceuticals and personal care products (PPCPs). The objectives of this research are: 1) to identify the presence of selected emerging contaminants (Acetaminophen, Bezafibrate, Caffeine, Carbamazepine, Cotinine, Diclofenac, Gemfibrozil, Ibuprofen, Metoprolol, Naproxen, Sulfadimethoxine, Sulfamethazine, Sulfamethoxazole, Sulfathiazole, Triclosan and Trimethoprim). These contaminants were selected based on analyte selection criteria such as occurrence and availability of analytical standards, chronological ecotoxicity and environment relevance concentration, volume of use, and priority ranking, as well as literature survey on environmental occurrence studies in local WWTPs; 2) to estimate the corresponding WWTPs' removal efficiency; and the third objective is to evaluate the feasibility of applying ultra-filtration (UF) membrane combined with pre-treatments - powder activated carbon (PAC), coagulation, and sand filtration to remove the above emerging contaminants. This paper appraises the efficacy of ultra-filtration membrane coupled pretreatments to mitigate the presence of pharmaceutical contaminants in water. This work is a sequel to an earlier work, Liu et al., published in 2014 ASME-IMECE conference proceedings. In this study, water samples were analyzed using direct aqueous injection High Performance Liquid Chromatography with Tandem Quadrupole Mass Spectrometric (LC/MS/MS) detection. Through the project research period, both historical concentrations from WWTPs and experimental removal efficiency data were obtained. Results showed that conventional WWTP failed to remove Carbamazepine, Diclofenac and Trimethoprim, and in some cases, the concentration of these contaminants at the effluent were higher than influent concentration. Secondly, the ultrafiltration membrane system by itself was insufficient to remove the selected contaminants. However, the use of PAC as a pretreatment to the UF system was effective in removing most of the contaminants, and the removal efficiency was a function of PAC dosage. Results indicated that there is an optimum dosage where the removal efficiency must be balanced with the cost of PAC. Unlike PAC, coagulation coupled with filtration process, was not able to increase the contaminants removal efficiency significantly. Additionally, the historical data indicated there was no dramatic fluctuation of the target contaminants level during the 12-month monitoring period.
机译:饮用水中的药物污染物可能会导致心脏病发作,器官损害,心理健康甚至癌症的风险增加。由于可能不知道它们的存在,发生的频率或来源,因此在水中发现的化学物以前从未被发现过,或者正在以可能与预期有显着差异的水平被发现。最近,去除新兴污染物被认为是高级废水处理厂(WWTP)系统中最重要的过程之一。 EPA正在努力增进对许多新兴污染物的了解,尤其是药品和个人护理产品(PPCP)。这项研究的目的是:1)识别某些新出现的污染物(对乙酰氨基酚,苯扎贝特,咖啡因,卡马西平,可替宁,双氯芬酸,吉非贝齐,布洛芬,美托洛尔,萘普生,磺胺二甲恶嗪,磺胺二甲嘧啶,磺胺甲恶唑,三甲氧嘧啶,磺胺噻吩, 。这些污染物是根据分析物选择标准选择的,例如分析标准物的出现和可用性,按时间顺序排列的生态毒性和与环境有关的浓度,使用量和优先级排序,以及有关当地污水处理厂环境发生研究的文献调查; 2)估算相应的污水处理厂的去除效率;第三个目标是评估将超滤(UF)膜与预处理相结合的可行性-粉末活性炭(PAC),混凝和砂滤以去除上述新兴污染物。本文评估了超滤膜耦合预处理减轻水中药物污染物存在的功效。这项工作是刘等人在2014年ASME-IMECE会议论文集上发表的较早作品的续篇。在这项研究中,使用直接水相进样高效液相色谱和串联四极杆质谱(LC / MS / MS)检测对水样进行分析。在整个项目研究期间,都获得了污水处理厂的历史浓度和实验去除效率数据。结果表明,常规污水处理厂无法去除卡马西平,双氯芬酸和甲氧苄氨嘧啶,在某些情况下,这些污染物在废水中的浓度高于进水浓度。其次,超滤膜系统本身不足以去除选定的污染物。但是,使用PAC作为超滤系统的预处理可以有效去除大多数污染物,去除效率是PAC用量的函数。结果表明,存在最佳剂量,其中去除效率必须与PAC的成本相平衡。与PAC不同,混凝和过滤过程不能显着提高污染物去除效率。此外,历史数据表明,在12个月的监测期内,目标污染物水平没有显着波动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号